Corporate Restructuring and Pipeline Focus Expected to Extend Cash Runway Amendment to Term Loan to Provide Additional Interest-Only Period LA JOLLA, Calif. , Aug. 9, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and
Efforts Aimed at Extending Cash Runway to mid-2019 LA JOLLA, Calif. , July 5, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced a strategic update and
Two pre-clinical programs advance towards clinical candidates Conference call today at 5:00 p.m. ET LA JOLLA, Calif. , May 10, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting
Conference Call and Webcast to Follow LA JOLLA, Calif. , May 3, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced it will provide first quarter 2018 financial
Initial safety and pharmacokinetic results from single ascending dose study support advancement LA JOLLA, Calif. , May 1, 2018 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs,
LA JOLLA, Calif. , April 17, 2018 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced Kathryn J. Collier has joined the Company's board of directors.
LA JOLLA, Calif. , March 20, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan , President and Chief Executive Officer of Regulus, will
Full enrollment of RG-012 studies anticipated in 2H 2018 RGLS4326 Phase I study on track Conference call today at 5:00 p.m. ET LA JOLLA, Calif. , March 7, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative
LA JOLLA, Calif. , March 5, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan , President and Chief Executive Officer of Regulus, will present
Conference Call and Webcast to Follow LA JOLLA, Calif. , Feb. 28, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced it will provide fourth quarter and
